Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma

被引:0
作者
E. Herrmann
N. Marschner
M. O. Grimm
C. H. Ohlmann
U. Hutzschenreuter
F. Overkamp
M. Groschek
K. Blumenstengel
G. Pühse
T. Steiner
机构
[1] University of Münster,Department of Urology
[2] Medical Practice for Oncology and Hematology,Department of Urology
[3] University of Dresden,Department of Urology
[4] University of the Saarland,Department of Urology
[5] Medical Practice for Oncology and Hematology,undefined
[6] Medical Practice for Oncology and Hematology,undefined
[7] Medical Practice for Oncology and Hematology,undefined
[8] Medical Practice for Oncology and Hematology,undefined
[9] University Hospital Jena,undefined
来源
World Journal of Urology | 2011年 / 29卷
关键词
Sorafenib; Sunitinib; Renal cell carcinoma; Sequential therapies;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:361 / 366
页数:5
相关论文
共 109 条
[1]  
Escudier B(2009)Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 3312-3318
[2]  
Eisen T(2009)Overall survival and updated results for Sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma J Clin Oncol 27 3584-3590
[3]  
Stadler WM(2008)Antitumour effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy J Urol 179 81-86
[4]  
Szczylik C(2008)Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis Eur Urol 54 1373-1378
[5]  
Oudard S(2009)Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 61-67
[6]  
Siebels M(2009)Sequentiel sorafenib and sunitinib for renal cell carcinoma J Urol 182 29-34
[7]  
Negrier S(2010)Is advanced renal cell carcinoma becoming a chronic disease? Lancet 376 574-575
[8]  
Chevreau C(2010)Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 1272-1280
[9]  
Solska E(2009)Final analysis of a large open-label, noncomparative, phase 3 study of sorafenib in European patients with advanced RCC (EU-ARCCS) Eur J Cancer Suppl 7 434-763
[10]  
Desai AA(2009)Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 757-undefined